Nula Therapeutics

Executive Summary

Nula Therapeutics is a preclinical-stage biotechnology company pioneering targeted protein degradation to address historically 'undruggable' oncogenic drivers. Leveraging its proprietary proteome-targeting platform, the company aims to develop first-in-class therapeutics for aggressive cancers with limited treatment options. While still in early development, Nula’s approach differentiates from traditional small molecules and antibodies by eliminating disease-causing proteins directly, potentially enabling the targeting of previously inaccessible pathways. The company is privately held, U.S.-based, and has raised an undisclosed amount of capital to advance its lead programs toward IND-enabling studies. With a focus on high-unmet-need indications, Nula represents an emerging player in the rapidly evolving field of targeted protein degradation, a modality that has attracted significant interest from large pharma. Key near-term milestones include optimization of lead compounds, completion of preclinical efficacy and toxicology studies, and preparation for regulatory filings. Success in these early stages will be critical to validating the platform and unlocking further financing or partnership opportunities.

Upcoming Catalysts (preview)

• Q2 2026Presentation of preclinical proof-of-concept data at a major oncology conference (e.g., AACR or ASCO)70% success
• Q4 2026IND filing for lead candidate40% success
• Q3 2026Series A financing round to support IND-enabling studies60% success